The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa, a phase III-ready investigational specialty medicine.

Under the agreement, GSK will acquire BP Asset IX, a subsidiary of Boston Pharmaceuticals, for up to $2 billion in total cash ...

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa.

Lockheed Martin lays off 64 Mass. clean energy workers Lockheed Martin lays off 64 Mass. clean energy workers © 2025 American ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...

London: GSK plc and Boston Pharmaceuticals, a clinical stage biopharmaceutical company developing highly targeted therapies ...

GSK GSK1.80%increase; green up pointing triangle will acquire a liver-disease treatment from Boston Pharmaceuticals for up to $2 billion as it seeks to boost its pipeline of new drugs. The British ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.